Strata Critical Medical (SRTA) Q2 2024 earnings summary

Executive summary

• Achieved first positive Adjusted EBITDA as a public company in Q2 2024, with both Medical and Passenger segments contributing to profitability.

• Total revenue rose 11.4% year-over-year to $67.9 million, driven by strong growth in both Medical and Passenger segments.

• Net loss improved to $(11.3) million from $(12.2) million in Q2 2023, with Adjusted EBITDA improving by $5.4 million to $1.0 million.

• Flight Profit increased 57.7% to $16.4 million, with Flight Margin expanding to 24.1% from 17.0% year-over-year.

• Liquidity remains strong with $142 million in cash and short-term investments and no debt at quarter-end.

Financial highlights

• Q2 2024 revenue: $67.9 million, up 11.4% year-over-year; Medical segment revenue reached $38.3 million, up 11.5% year-over-year and 6.4% sequentially.

• Medical segment Adjusted EBITDA rose 82.7% to $5.5 million; Passenger segment Adjusted EBITDA improved to $0.8 million from a loss of $2.1 million.

• Flight Margin rose to 24.1% from 17.0% in Q2 2023; gross profit more than doubled to $11.3 million, with gross margin rising to 16.7% from 8.3% year-over-year.

• Cash from operations was $8.4 million; capital expenditures totaled $16.9 million, mainly for aircraft acquisitions.

• Net loss per share improved to $(0.15) from $(0.17) in Q2 2023.

Outlook and guidance

• Reaffirmed 2024 and 2025 financial guidance, expecting continued revenue and Adjusted EBITDA growth.

• Medical revenue and Adjusted EBITDA expected to be flat in Q3 2024 before resuming low single-digit sequential growth.

• Passenger segment Adjusted EBITDA projected to improve year-over-year in Q3 and Q4 2024.

• Management expects sufficient liquidity to meet operational needs for at least the next 12 months.

• For 2025, expects double-digit year-over-year revenue growth and double-digit Adjusted EBITDA.